Koji Matsumoto

Dr. Koji Matsumoto

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2009 in Cancer Science
Verified
Journal Article
Open access
PDF file
MOMamiko Onuki
Mamiko Onuki
KMKoji Matsumoto
Koji Matsumoto
TSToyomi Satoh
Toyomi Satoh
AOAkinori Oki
Akinori Oki
SOSatoshi Okada
Satoshi Okada
HYHiroyuki Yoshikawa
Hiroyuki Yoshikawa
To obtain baseline data for human papillomavirus (HPV) screening and vaccination in Japan, we analyzed HPV DNA data from 2282 Japanese women (1517 normal cytology, 318 cervical intraepithelial neoplasia [CIN] grade 1, 307 CIN2–3, and 140 invasive cervical cancer [ICC]) that visited the University of Tsukuba Hospital or Ibaraki Seinan Medical Center Hospital for screening or treatment of cervical diseases between 1999 and 2007. An L1‐based PCR method was used for individual HPV genotyping. The most common HPV types in ICC were, in order of decreasing prevalence, HPV16 (40.5%), HPV18 (24.4%), HPV52 (8.4%), HPV58 (3.1%), and HPV33 (3.1%). Based on the comparison of HPV type distributions between normal cytology and CIN2–3 and ICC, estimated risk of disease progression varied considerably by genotype: HPV16, HPV18, HPV31, HPV33, HPV35, HPV52, and HPV58 (prevalence ratio, 1.92; 95% confidence interval 1.58–2.34); other oncogenic types (0.31, 95% confidence interval 0.19–0.50); and non‐oncogenic types (0.09, 95% confidence interval 0.03–0.43). HPV16 and/or HPV18, including coinfections with other types, contributed to 67.1% of ICC and 36.2% of CIN2–3 among Japanese women. More importantly, the overall prevalence of HPV16 and/or HPV18 varied greatly according to the women's age: highest in women aged 20–29 years (ICC, 90.0%; CIN2–3, 53.9%), decreasing with age thereafter, and lowest in women aged 60 years or older (ICC, 56.3%; CIN2–3, 25.0%). In conclusion, type‐specific HPV testing may help identify Japanese women at high risk of progression to CIN2–3 and cancer. In Japan, current HPV vaccines are estimated to provide approximately 70% protection against ICC and may be more useful in reducing the incidence of cervical cancer and precancer in young women of reproductive age. (Cancer Sci 2009; 100: 1312–1316)

23 August 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KMKoji Matsumoto
Koji Matsumoto
AOAkinori Oki
Akinori Oki
RFReiko Furuta
Reiko Furuta
HMHiroo Maeda
Hiroo Maeda
TYToshiharu Yasugi
Toshiharu Yasugi
FGfor Japan HPV And Cervical Cancer (JHACC) Study Group
for Japan HPV And Cervical Cancer (JHACC) Study Group
Only a subset of cervical precursor lesions progress to cervical cancer and because of the lack of the predictive markers, it cannot be ascertained which lesions will progress or not. To estimate the risk of disease progression associated with human papillomavirus (HPV) genotypes, we followed 570 Japanese women with cytological LSIL (low‐grade squamous intraepithelial lesion) and histological CIN (cervical intraepithelial neoplasia) grade 1–2 lesions (479 CIN 1; 91 CIN 2) at 3 to 4 month intervals for a mean follow‐up period of 39.1 months. At entry, we detected HPV DNA in cervical samples by polymerase chain reaction‐based methodology. Over the period of follow‐up period, 46 lesions progressed to CIN 3 while 362 regressed to normal cytology. Women with multiple HPV infections were more likely to have persistent lesions (hazard ratio [HR] for regression, 0.65; 95% confidence interval [CI], 0.42–1.02; p = 0.07); however, multiple infections did not increase the risk of progression (HR for progression, 1.04; 95% CI, 0.37–2.94; p = 0.94). After adjusting for CIN grade and women's age, HRs for progression to CIN 3 (vs. women with low‐risk types or negative for HPV DNA) varied markedly by HPV genotype: type 16 (11.1, 95% CI: 1.39–88.3); 18 (14.1, 0.65–306); 31 (24.7, 2.51–243); 33 (20.3, 1.78–231); 35 (13.7, 0.75–251); 52 (11.6, 1.45–93.3); 58 (8.85, 1.01–77.6); other high‐risk types (4.04, 0.47–34.7). HPV 45 was not detected in our study subjects. The cumulative probability of CIN 3 within 5 years was 20.5% for HPV 16, 18, 31, 33, 35, 52 and 58; 6.0% for other high‐risk types; 1.7% for low‐risk types (p = 0.0001). In conclusion, type‐specific HPV testing for women with LSIL/CIN 1–2 lesions is useful for identifying populations at increased or decreased risk of disease progression.

20 October 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SMShiho Miura
Shiho Miura
KMKoji Matsumoto
Koji Matsumoto
AOAkinori Oki
Akinori Oki
TSToyomi Satoh
Toyomi Satoh
HTHajime Tsunoda
Hajime Tsunoda
HYHiroyuki Yoshikawa
Hiroyuki Yoshikawa
Click on the article title to read more.

20 August 2010 in Cancer Science
Verified
Journal Article
Closed access
PDF file
KMKoji Matsumoto
Koji Matsumoto
AOAkinori Oki
Akinori Oki
RFReiko Furuta
Reiko Furuta
HMHiroo Maeda
Hiroo Maeda
TYToshiharu Yasugi
Toshiharu Yasugi
FGfor the Japan HPV And Cervical Cancer (JHACC) Study Group
for the Japan HPV And Cervical Cancer (JHACC) Study Group

6 August 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KMKoji Matsumoto
Koji Matsumoto
TYToshiharu Yasugi
Toshiharu Yasugi
SNShunsuke Nakagawa
Shunsuke Nakagawa
MOMitsuo Okubo
Mitsuo Okubo
RHRanko Hirata
Ranko Hirata
YTYuji Taketani
Yuji Taketani
The enhanced oncogenicity of particular human papillomavirus type 16 (HPV16) E6 variants is population‐dependent, implying the involvement of additional genetic cofactors. This study was designed to investigate the association between E6 variants and human leukocyte antigen (HLA) polymorphism within a Japanese population. Fifty‐seven women with HPV16‐positive cervical cancer were analyzed for E6 sequence variation and its relationship to HLA class II alleles. Compared with local controls (n = 138) and published controls (n = 916), DRB1*1501 and DQB1*0602 frequencies were significantly increased among patients with HPV16 E6 prototype (n = 11). Additionally, DRB1*1502 was positively associated with a particular E6 variant designated D25E (n = 25), although we could not find a significant association between HLA class II alleles and L83V variants (n = 16). Our observations suggest that a specific match between E6 variant proteins and HLA types may contribute to HPV16‐related cervical carcinogenesis.

17 June 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
KMKoji Matsumoto
Koji Matsumoto
AOAkinori Oki
Akinori Oki
TSToyomi Satoh
Toyomi Satoh
SOSatoshi Okada
Satoshi Okada
TMTakeo Minaguchi
Takeo Minaguchi
HYHiroyuki Yoshikawa
Hiroyuki Yoshikawa
Polymorphisms in cytokine genes can influence immune responses to human papillomavirus infection, possibly modifying risks of cervical cancer. Using an amplification refractory mutation system-polymerase chain reaction method, we analyzed a single nucleotide polymorphism (A/G) at position −1082 in interleukin-10 promoter region in 440 Japanese women: 173 women with normal cytology, 163 women with cervical intraepithelial neoplasia and 104 women with invasive cervical cancer. The carrier frequency of interleukin-10 −1082 G alleles associated with higher interleukin-10 production increased with disease severity: 9.8% for normal cytology; 19.6% for cervical intraepithelial neoplasia; 29.8% for invasive cervical cancer (P for trend <0.001). Among cytologically normal women, human papillomavirus infections were more common in those who were positive for an interleukin-10 −1082 G allele (P = 0.04). In conclusion, our data suggest that interleukin-10 −1082 gene polymorphism may serve as a marker of genetic susceptibility to cervical cancer among Japanese women.